Contact Us
Drug Search Results
More Filters [+]

Birinapant

Alternative Names: birinapant, tl32711
Latest Update: 2024-08-22
Latest Update Note: Clinical Trial Update

Product Description

A synthetic small molecule and peptidomimetic of second mitochondrial-derived activator of caspases (SMAC) and inhibitor of IAP (Inhibitor of Apoptosis Protein) family proteins, with potential antineoplastic activity.  (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/birinapant)

Mechanisms of Action: IAP Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: TetraLogic
Company Location: PAOLI NY 19301
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Birinapant

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Mesothelioma|Colorectal Cancer|Myelodysplastic Syndrome|Ovarian Cancer|Anal Cancer|NUT Carcinoma|Acute Myelomonocytic Leukemia|Fallopian Tube Cancer|Peritoneal Cancer|Esophageal Cancer|Small Cell Lung Cancer|Preleukemia|Squamous Cell Carcinoma|Acute Monocytic Leukemia|Chronic Myelomonocytic Leukemia|Juvenile Myelomonocytic Leukemia,|Gastrointestinal Cancer|Cholangiocarcinoma|Cervical Cancer|Head and Neck Cancer|Serous Cystadenocarcinoma|Oncology Solid Tumor Unspecified|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia|Acute Myeloid Leukemia

Phase 1: Squamous Cell Carcinoma|Head and Neck Cancer|Mouth Cancer|Facial Cancer|Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer|Hepatitis A|Hepatitis B, Chronic|Anal Cancer|Lymphoma|Nasopharyngeal Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NCI-2019-00175

P1

Terminated

Head and Neck Cancer|Nasopharyngeal Cancer|Squamous Cell Carcinoma

2023-11-15

19-C-0041

P1

Recruiting

Mouth Cancer|Facial Cancer|Head and Neck Cancer|Squamous Cell Carcinoma

2020-10-31

BPT-201

P2

Terminated

Esophageal Cancer|Colorectal Cancer|Cholangiocarcinoma|Gastrointestinal Cancer|Mesothelioma|Cervical Cancer|Small Cell Lung Cancer|Head and Neck Cancer|Squamous Cell Carcinoma|Anal Cancer|Ovarian Cancer|NUT Carcinoma

2020-02-17

HGSOC

P2

Withdrawn

Peritoneal Cancer|Ovarian Cancer|Serous Cystadenocarcinoma

2020-02-01

Recent News Events

Date

Type

Title

04/16/2024

PubMed

 Differential susceptibility of cells infected with defective and intact HIV proviruses to killing by obatoclax and other small molecules.

04/10/2024

PubMed

 Combination of bazedoxifene with chemotherapy and SMAC-mimetics for the treatment of colorectal cancer.

03/25/2024

PubMed

 Birinapant Reshapes the Tumor Immunopeptidome and Enhances Antigen Presentation.

02/15/2024

News Article

 MEDIVIR AB - YEAR-END REPORT JANUARY - DECEMBER 2023

12/06/2023

News Article

 Medivir to present at the Carlsquare Equity Research Investor Day

12/06/2023

News Article

 Medivir's partner IGM Biosciences announces strategic pipeline prioritization to extend its cash runway

12/05/2023

News Article

 IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions